Oncolytics Biotech Inc. (ONCY)
$0.49+4.26%Close
SELLCRISIS · day 16
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $49M
- Beta
- 1.16
- P/E (TTM)
- -2.02
- Short % float
- 6.31%
- Days to cover
- 7.2
- SI change
- -14.7%
- 1W
- -18.33%
- 1M
- -39.51%
- vs SPY 1W
- -18.19%
- vs SPY 1M
- -42.01%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 6
- VALUE
- 7
- GROWTH
- 36
- GARP
- 0
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-
REV YoY-
ROE-
EPS YoY-
ROA-498.1%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-2.02
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B-13.52
P/FCF-
EV/EBITDA-1.74
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO1.35
ND/EBITDA-
BETA1.16
Company news
FAQ
- What is LOPJLB’s current signal on ONCY?
- LOPJLB’s latest quantitative signal on Oncolytics Biotech Inc. (ONCY) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is ONCY in?
- Oncolytics Biotech Inc. (ONCY) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Oncolytics Biotech Inc. (ONCY) do?
- Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal ad…